Testing a new multiple myeloma drug with other treatments
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study tests how safe a new drug (CC-92480) is and how much it stays in the body, when given with other standard or study treatments. It’s for people whose multiple myeloma has come back or did not respond after prior therapy, with the goal of improving disease control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your multiple myeloma has returned or worsened after your last treatment
- You have measurable (trackable) myeloma in your body
- You can do most daily activities (performance score 0 or 1)
- You can’t take it if you’ve had a recent history of problems in the brain/spinal cord from myeloma
- If you’ve had certain prior drugs or treatments (including this study drug), you may not qualify
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This study is testing new drugs for people recently diagnosed with multiple myeloma, a blood cancer. It aims to see if the new treatment is safe and effective, and it may offer an additional treatment option.
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.